We performed a retrospective analysis on 421 adult patients who underwent unrelated cord blood transplantation (UCBT) for ALL. Median age was 32 years; 46% were in first CR (CR1), 32% in CR2 and 22% had advanced disease. Double UCBT was performed in 173 patients (41%). Myeloablative conditioning (MAC) was given to 314 patients (75%). Cumulative incidence (CI) of 60-day neutrophil recovery was 78%. CI of acute and chronic GVHD was 33 and 26%, respectively. Non-relapse mortality (NRM) at 2 years was 42%. Age ⩾ 35 years (P o 0.0001), advanced disease at UCBT (P o 0.0001) and use of MAC (P o 0.0001) were associated with increased NRM. Relapse incidence (RI) at 2 years was 28%; use of reduced intensity conditioning (RIC) (P = 0.0002) was associated with increased RI. Two-year leukemia-free survival (LFS) was 39% for patients in CR1, 31% for CR2 and 8% for advanced disease. In multivariate analysis, factors associated with decreased LFS rate were: age ⩾ 35 years (P = 0.034), use of MAC (P = 0.032) and advanced disease (P o0.0001). These results show that UCBT is a valuable option to treat high-risk adult ALL when in remission. Strategies to decrease toxicity and relapse are needed to improve final outcomes.
INTRODUCTION
Approximately one-third of adults with ALL achieve long-term survival after conventional chemotherapy. 1 Therefore, many prospective trials have described prognostic factors to identify those patients who could benefit from allogeneic hematopoietic SCT (allo-HSCT). [1] [2] [3] [4] The most recognized high-risk features at diagnosis are age above 35 years, elevated WBC count, time from diagnosis to first remission, cytogenetics and the persistence of minimal residual disease after induction and consolidation. 5 Besides some controversy about which patients and when they should undergo allo-HSCT, it remains the best curative option for younger patients with high-risk disease. 6, 7 For patients lacking an HLA-matched donor, HLA-mismatched umbilical cord blood (CB) has become an alternative stem cell source. CB units (CBUs), which importantly expand donor availability, have emerged as a major alternative graft source. 7 The progress in the use of CB cells in adults is due to the increased number of CB banks and CBUs available, the development of reduced intensity conditioning (RIC) regimens and the use of double CBUs to circumvent the cell dose problem. Different comparative studies on stem cell sources reported similar outcomes after unrelated donor allo-HSCT or unrelated CB transplantation (UCBT) for adults with acute leukemias. [8] [9] [10] [11] [12] To date, only a few studies have critically assessed the overall outcomes after UCBT for adult ALL. [13] [14] [15] To describe outcomes and risk factors after UCBT for adult ALL, with the aim to evaluate whether it is a suitable option to treat this population, we designed a retrospective registry-based analysis including 421 patients who received UCBT in European group for blood and marrow transplantation (EBMT) centers.
PATIENTS AND METHODS

Eligibility criteria
The following eligibility criteria were used to select patients in the Eurocord database: adults (⩾18 years) with ALL who received an UCBT in EBMT transplantation centers from 2000 to 2011. A total of 593 adult patients with ALL were selected from the Eurocord database. Of these, 80 were excluded because they received an expanded or manipulated CBU. Another 70 patients had previous allo-HSCT and 22 were excluded due to lack of outcome data at the time of analysis. A total of 421 patients were considered for this study, of whom 57 have been previously described, 10 however, with updated follow-up. Median follow-up of survivors was 30 months (range 4-120); 70 patients had follow-up o2 years.
Data collection
Data on patients, graft characteristics and outcomes were collected using the Eurocord and EBMT forms. Clinical and outcome data were validated and checked for errors and discrepancies by a hematologist (LT) in Eurocord office. Data managers and physicians in each EBMT center were requested to check and complete missing data and update patient's follow-up. All participating centers received the synopsis of the study and gave their written approval. The Institutional Review Boards of the Eurocord-ALWP scientific committee approved this study. According to EBMT rules, patients gave informed consent for data entry into the EBMT and Eurocord registries databases and for its use for analysis in accordance with the Declaration of Helsinki.
Endpoints, definitions and statistical analysis
The primary endpoint was 2-year leukemia-free survival (LFS). Neutrophil recovery was defined as achieving absolute neutrophil count ⩾ 0.5 × 10 9 /L for 3 consecutive days. Full donor chimerism was defined as ⩾ 95% leukocytes of donor origin in peripheral blood or marrow, measured by different techniques according to transplantation center. Autologous reconstitution was defined as ⩾ 95% leukocytes of recipient origin. Mixed chimerism was defined by the presence of >5% but o95% of leukocytes of donor origin. Neutrophil engraftment was defined as neutrophil recovery not considering patients who presented autologous reconstitution. The diagnosis and grading of acute and chronic GVHD (aGVHD and cGVHD) were assigned by the transplantation center using standard criteria. 16 Relapse and death from any cause were considered events. Nonrelapse mortality (NRM) was defined as death without prior relapse. LFS was calculated from the date of UCBT until death, relapse or last diseasefree follow-up. OS was calculated from the date of UCBT until death or last observation alive.
Patients were divided into three cytogenetic risk groups, as previously described by Moorman et al.:
17 very high risk (t(9;22)), high risk (t(4;11), t(8;14), t(14;18), low hypodiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes) and complex karyotype) and standard risk (all others). Given the small number of patients in the high-risk group, we also performed an analysis considering only the presence of Philadelphia chromosome. Analysis was performed as of October 2012 and updated in September 2013 with no significant differences in follow-up or outcomes. Median values and ranges were used for continuous variables and percentages for categorical variables. For each continuous variable, the study population was initially divided into quartiles and into two groups by the median. The median value was found to be the best cutoff for analysis of outcomes.
Clinically relevant variables were included in the prognostic factor analysis. As the use of anti-thymocyte globulin (ATG) varied among protocols and details on administration, type and dose of ATG were not reported, it was not included in the main multivariate model. However, given its association with outcomes in univariate analysis, we built a second multivariate model including ATG (data shown as Supplementary Information).
Probabilities of OS and LFS were calculated using the Kaplan-Meier method and the log-rank test for univariate comparisons. Probabilities of neutrophil engraftment, grade II-IV acute and chronic GVHD, relapse and NRM were calculated with the cumulative incidence (CI) estimator using death or relapse as a competing event. Multivariate analyses were performed using Cox proportional hazards regression model for LFS and OS, and Fine and Gray's proportional hazards regression model for other outcomes. Variables that reached a P-value of 0.15 in the univariate analysis (except ATG) were included in the initial models and variables were eliminated once at a time in a stepwise manner to only keep variables that reached a P-value of 0.05 in the final model. P-values were two-sided. Statistical analyses were performed with SPSS (SPSS Inc., Chicago, IL, USA) and SPLUS (MathSoft Inc., Seattle, WA, USA).
RESULTS
Patients, disease and graft characteristics
Patients and transplantation characteristics are summarized in Table 1 . Median age was 32 years (range 18 to 76). At UCBT, 46% of patients (n = 195) were in first CR (CR1), 32% (n = 136) in CR2 and 22% (n = 90) had advanced disease. Almost half of the patients transplanted in CR1 were older than 35 years at diagnosis (48%, n = 94). In this group, median time to achieve CR was 43 days and median time from diagnosis to transplantation was 7 months. Information on cytogenetics at diagnosis was available for 75% (n = 314) of patients. The frequency of very high-risk group (n = 129) was 45% (n = 89) in CR1, 17% (n = 23) in CR2 and 19% (n = 17) in those with advanced disease.
Double UCBT was performed in 173 patients (41%) and the median total nucleated cell dose at freezing was 3.5 × 10 7 /kg for single and 4.7 × 10 7 /kg for double UCBT. Most patients received UCBT with one (25%, n = 103) or two (55%, n = 231) HLA disparities out of six. Only nine patients (2%) received a 6/6 matched CBU and 26 patients (6%) received units with three mismatches. Myeloablative conditioning (MAC) was given to 75% (n = 314) of the patients, of which 59% (n = 184) were TBI based. Out of 129 patients who received a BU-based MAC, 106 patients received a combination of BU, thiothepa and CY (n = 27) or fludarabine (n = 79). Another 10 patients received BU+CY. We did not find any difference in outcome (RI, TRM, LFS or OS) when comparing patients receiving a TBI-or BU-based MAC regimen (data shown in supplementary information). RIC regimen consisted of CY, fludarabine and 2 Gy TBI in 71% (n = 73) patients. As GVHD prophylaxis, a combination of CYA and mycophenolate mofetil was given for 46% (n = 193) of the cases. The frequency of ATG administration as part of the conditioning regimen was statistically different among patients who received either a myeloablative (MAC) or an RIC: 70% (n = 212), for MAC and 30% (n = 25), for RIC, Po 0.0001. Engraftment A total of 329 patients achieved neutrophil engraftment in a median of 24 days (range 6-78). The CI of 60-day neutrophil engraftment was 78 ± 2%. It was 79 ± 3% for patients in CR1, 84 ± 3% in CR2 and 65 ± 5% for patients transplanted with advanced disease (P = 0.007). Factors influencing neutrophil engraftment in univariate analysis are listed in Table 2 . In multivariate analysis, female gender (hazard ratio (HR) = 1.3; 95% confidence interval (CI) = 1.0-1.6; P = 0.03), remission status (HR = 1.5; 95% CI = 1.1-2.0; P = 0.02) and UCBT performed after 2008 (HR = 1.4; 95% CI = 1.1-1.8; P = 0.005) were associated with greater engraftment. Of the 89 patients who did not reach engraftment, 76 died in a median time of 43 days (range 2-383) after the UCBT. Of the 13 patients who are alive, information on subsequent treatment was available for nine: five patients received a second allograft (four patients received peripheral blood from mismatched related donors and one another CBU) and four patients had autologous recovery followed by a nontransplantation treatment.
Chimerism analysis during the 100 days after UCBT was reported for 264 out of 329 who engrafted: 241 had full donor and 23 had mixed chimerism.
Acute and Chronic GVHD Overall 193 patients developed aGVHD within a median of 20 days (range 4-91) after UCBT: 136 patients experienced grades I-II and 57 grades III-IV. The CI of aGVHD at 100 days was 33 ± 2% and the CI of grades III-IV aGVHD was 13 ± 2%. On multivariate analysis, no factors were associated with aGVHD. cGVHD was observed in 102 patients at risk; 43 presented with extensive disease. CI of cGVHD was 26 ± 2%.
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Relapse CI of relapse (RI) at 2 years was 28 ± 2% and the median time to relapse was 5 months (0.4-48). RI was similar among the three cytogenetic risk groups (Table 2 ). RI was 23% for patients in CR1, 34% for patients in CR2 and 31% for those transplanted with advanced disease. Of note, most patients in the latter group died of transplantation-related causes in a median time of 72 days after UCBT. In multivariate analysis, use of RIC was associated with greater RI (HR = 1.8, 95% CI = 1.2-2.7, P = 0.0002) ( Table 3 , Figure 1 ).
NRM and causes of death
A total of 168 patients died from non-relapse causes in a median of 88 days after UCBT (range 2-1256). Among them, 92 (55%) died from infection, 28 (17%) from GVHD, 22 (13%) from multiorgan failure/acute respiratory distress syndrome, 14 (8%) from graft failure, 7 (4%) from sinusoidal obstruction syndrome and 5 (3%) from other causes. A 100-day CI of NRM was 23 ± 2% and 2-year CI of NRM was 42 ± 2%. In multivariate analysis, age ⩾ 35 years at UCBT (HR = 1.9; 95% CI = 1.4-2.6; P o 0.0001), advanced disease status (HR = 2.3; 95% CI = 1.6-3.3; P o0.0001) and use of MAC (HR = 2.7; 95% CI = 1.7-4.3; P o 0.0001) were associated with increased risk of NRM ( Figure 2 ).
Leukemia-free survival and OS Two-year LFS was 39% for patients in CR1 (n = 195), 31% for CR2 (n = 136) and 8% for patients with advanced disease (n = 90), P o0.0001 (Table 2, Figure 3) . In multivariate analysis, three factors were associated with decreased LFS: age ⩾ 35 years (HR = 1.3; 95% CI = 1.1-1.7; P = 0.034), advanced disease status (HR = 2.8; 95% CI = 2.2-3.7; P o0.0001) and use of MAC (HR = 1.4; 95% CI = 1.1-1.9; P = 0.032). Two-year OS was 51 ± 4% for patients in CR1, 40 ± 4% for CR2 and 11 ± 3% for those with advanced disease (P o 0.0001). The same unfavorable risk factors found for LFS were associated with OS. Survival was not significantly different among the cytogenetic risk groups (Table 2 ).
In the univariate analysis, the use of ATG was associated with decreased LFS and OS (Table 2) . Given these results, we first analyzed separately the impact of ATG in patients transplanted after MAC and RIC (Supplementary Table 2 , Supplementary Information). The use of ATG was associated with decreased LFS (HR = 1.4; 95% CI = 1.1-1.9; P = 0.02, Supplementary Table 3, Supplementary Information).
DISCUSSION
Our study shows that UCBT is a suitable option to treat young adults with high-risk ALL when transplanted in remission.
We have analyzed a high-risk adult ALL cohort, as patients transplanted in CR1 presented one or more high-risk features at diagnosis. Although there is no consensus regarding the indications for allo-HSCT in adult ALL in first CR, it is important to know that patients lacking an HLA-matched donor can also benefit from this treatment option. 5, 6 In high-risk patients, the conventional chemotherapy treatment leads to a remission rate of 80-90%, but long-term survival is not superior to 35%. 18 Previous studies had already demonstrated that results after related and unrelated allo-HSCT for adults with ALL were similar. [19] [20] [21] Allo-SCT from related or matched unrelated donors results in 5-year OS from 40-50% in high-risk patients. Autologous HSCT may be considered in patients lacking a donor, with similar results but higher relapse incidence. 18 In the absence of an HLA-matched donor, CB cells can be used as an alternative source of allo-HSCT. The Spanish group has reported outcomes of 62 high-risk ALL patients receiving UCBT compared with 87 transplanted with matched unrelated donor grafts, with no significant differences in RI, LFS or OS. 12 Data on outcomes after UCBT for ALL adult patients are scarce. [13] [14] [15] One Japanese series reported in 2009 outcomes of Abbreviations: cGVHD = chronic GVHD; LFS = leukemia-free survival; RIC = reduced intensity conditioning; UCBT = unrelated cord blood transplantation.
a Double UCBT RR = 0.9 (0.8-1.1), P = 0.07. 27 patients in all-disease status transplanted after MAC, with an LFS of 57% at 5 years. Analysis of risk factors was not done. 13 In the same year, the Minnesota group published the results on 22 patients, of whom 18 were transplanted with CB and 4 with related donors, all of them after RIC.
14 More recently, Matsumura et al. 15 published the largest analysis to date on UCBT for adult ALL, with 256 patients in all-disease status transplanted either after MAC or RIC. The 2-year LFS was 36%, with RI of 43% and TRM of 42%, and factors associated with lower survival rates were age ⩾ 51 years, advanced disease at UCBT, presence of aGVHD and absence of cGVHD. The aim of our study was to describe risk factors for outcomes in a large series of UCBT adult recipients with ALL. We found that patients older than 35 years, as well as those transplanted in advanced disease, have a significant decrease in LFS mainly due to increased NRM. Age and disease status are known factors negatively associated with survival in adult ALL. 1 Bachanova et al.
14 reported a 3-year OS of 81% in 12 patients transplanted in CR1 after RIC (CY+fludarabine+TBI 2 Gy), with an NRM of 8%. In our study, the use of MAC was associated with increased NRM leading to both decreased LFS and OS. On the other hand, the use of RIC was significantly associated with increased RI. The role of RIC in adult ALL has been addressed in several retrospective studies. In a series of 449 patients transplanted in CR1 reported by the EBMT group, LFS after RIC or MAC was not statistically different, as a result of lower NRM but increased RI in patients transplanted after RIC. 22 Other retrospective studies have not shown any statistically different results between RIC and MAC in patients with ALL. 19, 23 All these data support RIC as a feasible option to treat adult ALL. Nevertheless, it is not possible to show a potential advantage of this less toxic approach on transplantation outcome, as the retrospective nature of the studies cannot avoid selection bias and heterogeneity of patients and treatment.
In our study, the univariate analysis showed that the use of ATG is associated with an overall decreased LFS, as a result of both increased NRM (especially in patients transplanted after RIC) and relapse incidence (in those transplanted after MAC). Indeed, patients who received ATG as a part of conditioning had decreased risk of aGVHD, both after MAC and RIC. However, in patients transplanted after MAC, there was a trend to increased RI associated with the use of ATG. In patients transplanted after RIC, the use of ATG was associated with increased NRM. Overall, the use of ATG was associated with decreased LFS and the difference was also observed when analyzing separately the patients transplanted after RIC or MAC. Despite the fact that some studies have shown decreased incidence of acute and mainly chronic GVHD without increasing RI in patients who received ATG as a part of conditioning for matched unrelated donor transplantation, this did not translate into decreased NRM or increased survival. 24, 25 Besides, the role of ATG in the RIC setting is not clear and there are no studies focusing on UCBT. 26 These results raise the important question whether the use of ATG as a part of the conditioning regimen for UCBT in adult ALL is negatively associated with outcome, and our preliminary findings merit further investigation.
The importance of the effect of cell dose on outcome after UCBT was demonstrated by our group and others, and today it is consensual that a minimum of pre-freezing total nucleated cells ⩾ 2.5 × 10 7 /kg dose is required. 27, 28 In this study there was no impact of cell dose on outcome. Of note, less than 10% patients transplanted with a single CBU received a total nucleated cell dose below the recommended threshold. In fact higher cell dose was associated with improved LFS and OS in univariate analysis but not in the multivariate model, as disease status, age and conditioning regimen were strongly associated with those outcomes. Despite the results in univariate analysis showing that double UCBT was associated with improved LFS, graft type was not isolated as a risk factor in the final multivariate model probably because the type of graft was related to the disease status at transplantation, that is, more patients with advanced disease received a single CBU compared with patients transplanted in CR (data not shown). Indeed, in the literature it is still controversial if double CBU is associated with higher a GVL effect and improved outcome; [29] [30] [31] [32] [33] and to address this question, a specific study designed to address this question has to be performed.
Most of the patients analyzed in our study were transplanted in CR1 (n = 195) and all but four of them had one or more high-risk features at diagnosis, including very high-or high-risk cytogenetics, high WBC count or age older than 35 years. We did not find any statistical association of outcomes after UCBT with cytogenetic risk stratification according to Moorman et al. 17 , SWOG 34 (data not shown) neither when analyzing specifically the impact of Philadelphia chromosome. Despite remaining a major risk factor in ALL, 2,35 outcomes of Philadelphia-positive patients have markedly improved after the introduction of tyrosine kinase inhibitors in treatment protocols, before and after allo-SCT. 36, 37 The fact that 75% of our patients were transplanted after 2006, when tyrosine kinase inhibitors were already largely used in the first line treatment of Philadelphia-positive ALL, may explain the similar results. An important limitation of our study was the absence of data on minimal residual disease. The assessment of minimal residual disease after induction and consolidation has emerged as a fundamental pretransplantation risk factor in the definition of the best therapeutic option for each individual patient. 38 Studies addressing the impact of minimal residual disease status on outcome after UCBT for adult ALL are still lacking.
In conclusion, our data suggest that UCBT is a valuable option to treat high-risk adult ALL. NRM remains a limitation, mainly in patients older than 35 years. Given our results, UCBT should be offered to adult ALL patients in hematological remission with an indication for allo-HSCT and lacking an HLA-matched donor. More studies addressing the results after RIC, the impact of double CBU and the role of ATG in UCBT will help to develop strategies to minimize the toxicity and improve outcomes after transplantation. P<0.0001 Figure 3 . Two-year leukemia-free survival according to disease status at UCBT.
